Novartis pays up to $1 billion for potential eczema drugSwiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to Share XNovartis pays up to $1 billion for potential eczema drughttps://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/
